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Abstract: LMNA encodes for Lamin A/C, type V intermediate filaments that polymerize under the
inner nuclear membrane to form the nuclear lamina. A small fraction of Lamin A/C, less polymerized,
is also found in the nucleoplasm. Lamin A/C functions include roles in nuclear resistance to
mechanical stress and gene regulation. LMNA mutations are responsible for a wide variety of
pathologies, including Emery–Dreifuss (EDMD) and LMNA-related congenital muscular dystrophies
(L-CMD) without clear genotype–phenotype correlations. Both diseases presented with striated
muscle disorders although L-CMD symptoms appear much earlier and are more severe. Seeking
for pathomechanical differences to explain the severity of L-CMD mutations, we performed an in
silico analysis of the UMD-LMNA database and found that L-CMD mutations mainly affect residues
involved in Lamin dimer and tetramer stability. In line with this, we found increased nucleoplasmic
Lamin A/C in L-CMD patient fibroblasts and mouse myoblasts compared to the control and EDMD.
L-CMD myoblasts show differentiation defects linked to their inability to upregulate muscle specific
nuclear envelope (NE) proteins expression. NE proteins were mislocalized, leading to misshapen
nuclei. We conclude that these defects are due to both the absence of Lamin A/C from the nuclear
lamina and its maintenance in the nucleoplasm of myotubes.
Keywords: Emery–Dreifuss muscular dystrophy; LMNA-related congenital muscular dystrophy;
Lamin A/C; LMNA
1. Introduction
In eukaryotic cells, DNA is separated from the cytoplasm by the nuclear envelope (NE). The NE is
composed of two lipid bilayers: the outer nuclear membrane (ONM) facing the cytoplasm and directly
connected to the endoplasmic reticulum, and the inner nuclear membrane (INM) facing DNA. The
INM and the ONM are interconnected at the nuclear pores, allowing for the shuttling of proteins
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and RNAs between the nucleus and the cytoplasm. The INM is characterized by a subset of integral
membrane proteins termed nuclear envelope transmembrane proteins (NETs) [1]. Underneath the
INM is the nuclear lamina, composed of A- and B-type Lamins. The LMNA gene encodes for Lamin A
and Lamin C, whereas LMNB1 and LMNB2 encode for Lamin B1 and Lamin B2, respectively. While
B-type Lamins are ubiquitously expressed, A-type Lamin expression is developmentally controlled
and appears as tissues differentiate [2].
As with all intermediate filaments, Lamin proteins are comprised of three domains: a short
unstructured head domain at the N-terminus, a central helical rod domain and a non-helical C-terminal
domain. The central rod domain is subdivided in three subdomains: coil 1a, coil 1b and coil 2 that are
interrupted by linker segments L1 and L12 (Figure 1A). This long rod domain has a high propensity
to form coiled–coil dimers, at the basis of the Lamin assembly into dimers. These coiled–coil dimers
further assemble in a head-to-tail manner by interactions between charged residues of coil 1a and
coil 2 of one dimer with the unstructured head and tail of adjacent dimers [3,4]. Compared to other
intermediate filaments, A- and B-type Lamins have two specific sequences in their unstructured
tail domain: an NLS (Nuclear Localization Signal) responsible for their nuclear localization and an
immunoglobulin-like fold domain that is involved in multiple protein–protein interactions. Except
for Lamin C, Lamins contain a C-terminal CaaX motif that is post-transcriptionally prenylated and
carboxymethylated, thus anchoring them to the INM. Lamin A is further processed to remove the 15
last amino acids in order to generate mature Lamin A [5].
Depending on its level of phosphorylation, A-type Lamins are able to assemble under the INM
(their main localization) or to reside in the nucleoplasm [6]. The presence of A-type Lamins at the
nuclear periphery is required for the nuclear sequestration of NETs [7–10] and for the interaction with
the cytoskeleton via the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex [11]. Functions
of A-type Lamins include regulation of gene transcription, DNA repair, regulation of cell cycle and
mechanotransduction [12–14].
LMNA mutations are responsible for a wide range of diseases, termed laminopathies, which
affect various tissues in an isolated (striated muscle, adipose tissue or peripheral nerve) or systemic
(premature aging syndromes) fashion [15,16]. Most laminopathies lead to striated muscles disorders
and include LMNA-related congenital muscular dystrophy (L-CMD), Emery–Dreifuss muscular
dystrophy (EDMD), limb-girdle muscular dystrophy type 1B (LGMD-1B) and dilated cardiomyopathy
with conduction defects (DCM-CD). These four entities, all share the same cardiac dysfunction,
but present with decreasing severity of skeletal muscle symptoms, L-CMD being the most severe
LMNA-related muscular dystrophy [17]. To date, the lack of knowledge regarding the pathophysiology
of these different striated muscle laminopathies is a substantial hurdle for the development of adapted
therapies [18].
In this study, we performed in silico analyses of the UMD-LMNA locus specific mutation database
and used fibroblasts from EDMD and L-CMD patients as well as myoblasts from EDMD and L-CMD
mouse models to seek differences between these two muscular dystrophies. We found that L-CMD
patients harbor significantly more mutations in residues involved in Lamin dimer and tetramer
interactions and stabilization. In line with this, we showed an increased proportion of Lamin A/C
within the nucleoplasm of L-CMD patient and mouse cells. Additionally, using mouse primary
myoblasts derived from EDMD [19], and L-CMD [20] mouse models, we showed that the absence of
Lamin A/C from the nuclear periphery and its accumulation in the nucleoplasm are highly detrimental
for myoblast differentiation. This is in part due to the inability of L-CMD post-mitotic myocytes to
sequester muscle specific NET in the nuclear envelope required for chromatin remodeling. Finally, using
Lmna-KO myoblasts and myoblast in which Lamin A/C was artificially displaced to the nucleoplasm,
we were able to show that the absence of Lamin A/C from the nuclear periphery and maintenance of
nucleoplasmic Lamin A/C in myotubes are involved in the phenomenon.
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2. Material and Methods
2.1. The UMD-LMNA Locus Specific Database
The UMD-LMNA database (www.UMD.be/LMNA/) was developed since 2001 using the “Universal
Mutation Database” (UMD) tool [21]. It aims to gather all published LMNA definitely mutated patients
(probands as well as their relatives) in order to provide up-to-date information about mutations for
the scientific community. The mutations are collated from published articles, congress abstracts and
from personal communications transmitted to the curators (R. Ben Yaou and G. Bonne). If patients
are reported several times, they are captured only once in UMD-LMNA. The database also includes
the LMNA mutations submitted to the LMNA Leiden open database (https://databases.lovd.nl/shared/
genes/LMNA) that are freely and publicly available. For each reported patient, several data levels
are captured including mutation details at nucleotide level (exon and codon number, wild type and
mutant codon, mutational event, mutation name), amino acid level (wild type and mutant amino acid),
RNA level when RNA consequence studies were performed by the authors and at the clinical level.
For the latter, a phenotypic group defined from provided clinical data (mode of onset, the presence or
absence of skeletal muscles, heart as well as the other tissue involvements described in laminopathies)
is linked to each patient. The database currently includes 2454 published (511 papers or congress
abstracts) and 702 unpublished subjects.
2.2. Cells
2.2.1. Human Primary Fibroblasts
All experiments were performed in accordance with the French legislation on ethical rules.
Patient skin fibroblasts were collected with informed consent from four unrelated patients with the
following LMNA mutations: LMNA p.His222Pro, LMNA p.Arg453Trp, LMNA p.Lys32del and LMNA
p.Arg249Trp. At the time of biopsy, patients were 13, 24, 3, and 3 years old, respectively. Clinical details
of the patient carrying LMNA p.His222Pro with EDMD was previously reported and correspond to
patient VI-7 in family EMD3 [17]. The patient with LMNA p.Arg453Trp was diagnosed with EDMD (M.
Hirano, personal communication). Clinical details of patients with LMNA p.Lys32del and p.Arg249Trp
(both L-CMD) were also previously reported and correspond to P9 and P2, respectively [22]. Control
fibroblasts were obtained from a 26 years old control subject without muscular disorders. Cells were
expanded in DMEM containing 10% fetal bovine serum and 1% penicillin/streptomycin. All cells were
grown in a humidified incubator at 37 ◦C in 5% CO2. All followed procedures were in accordance
with the ethical standards of the responsible committee on human experimentation (institutional and
national).
2.2.2. Mouse Primary Myoblasts
All mouse procedures were done according to protocols conformed to French laws, and regulations
concerning the use of animals for research were approved by an external ethical committee (approval
No. 00972.03 and 00979.03; delivered by the French Ministry of Higher Education and Scientific
Research). Mouse myoblasts were extracted from muscles of H222P (corresponding to Lmnatm1Gbon
according to MGI nomenclature; on 129S2/SvPasOrlRj background) and dK32 mice (corresponding to
Lmnatm2.1Gbon according to MGI nomenclature; on C57BL/6JRj background) models and their respective
controls. Lmna-KO mouse primary myoblasts (corresponding to Lmnatm4.1Stw according to MGI
nomenclature; on 129P2/OlaHsd background) and corresponding controls were generously given
by Colin Stewart [2]. All mouse primary myoblasts were expanded on 1% Matrigel (BD Bioscience,
Corning, Avon, France) in DMEM supplemented with 20% fetal bovine serum (ATCC), 10% donor
horse serum (VWR International, Fontenay-sous-Bois, France), and 1% chicken embryo extract (Life
Science Group, Wilden, UK). Differentiation was achieved by high cell density on 10% Matrigel (BD
Bioscience) in differentiation medium (DMEM supplemented with 2% donor horse serum and 0.5%
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Chicken Embryo Extract). All media contained 1% penicillin/streptomycin. All cells were grown
in a humidified incubator at 37◦C in 5% CO2. For immunofluorescence, mouse primary myoblast
were plated on Permanox lab-tek culture chambers (Nunc, ThermoFisher Scientific, Illkirch, France) or
ibi-Treat coated µ-slides (iBidi, Biovalley, Marne-la-Vallée, France).
2.2.3. Lentiviral Vector Production and Transduction
Four different Myc-tagged DARPins targeting Lamin A/C (LaA_1, LaA_2, LaA_3 and
LaA_4) and control myc-tagged DARPin (E3.5) were generously provided by Ohad Medalia [23].
Coding sequences were received in pEGFP-N1 plasmid where EGFP was replaced by IRES-GFP
(pEGFP-DARPin-IRES-GFP plasmids). Subcloning of the different myc-tagged DARPins into an
HIV-derived vector plasmid (pRRL-SIN-cPPT-DesminGFP-HYGRO-WPRE, hereafter pRRL-EGFP)
plasmid was achieved by digestion of pEGFP-DARPin-IRES-GFP plasmids by Nhe I/Pml I and ligation in
place of EGFP within the XbaI/Pml I sites of pRRL-EGFP, and grown in STBL2 bacteria (ThermoFischer
Scientific, Illkirch, France) at 32 ◦C. Plasmid purifications was performed using NucleoSpin Plasmid
kits from Macherey Nagel. The integrity of plasmid sequences was validated by sequencing. Stocks of
vesicular stomatitis virus GP pseudotyped self-inactivating lenti-viral vectors were produced in 293
T cells using a four-plasmid system as described previously [24]. Supernatant was collected during
4 days and added to mouse primary myoblast culture medium at a 1:2 and 1:4 ratio. Three days
post-infection, cells were split for further amplification with proliferation medium containing 50 µg/mL
Hygromycin (Thermofisher scientific, illkirch, France) for 3 weeks for the specific selection of DARPin
positive myoblasts.
2.3. Drug Treatments
Proliferating myoblasts and 4 day-differentiating myotubes were treated with 10 µM EdU for 3h
before fixation with 4% PFA for 10min followed by immunofluorescence according to manufacturer’s
protocol (Clik-iT EdU #C10337; Life technologies).
Mouse primary myoblasts were placed in differentiation medium for 24h. Cells were then treated
for 2h with 5 µg/mL nocodazole (Sigma-Aldrich, Saint Quentin Fallavier, France) in differentiation
at 37 ◦C/5% CO2. Nocodazole was then washed out by a quick wash with differentiation medium
followed by a 4 min wash with differentiation medium at 37◦C/5% CO2. Cells were immediately
pre-extracted with 1% Triton in PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM
MgCl2, pH 6.9) for 30 sec and fixed with 4% PFA before proceeding for immunofluorescence.
2.4. Immunofluorescence
Human control and patient fibroblasts were grown on glass coverslips. Proliferating and
4-day-differentiating myoblasts were grown on Permanox lab-tek culture chambers (Nunc) or ibi-Treat
coated µ-slides (iBidi). All cell types were fixed for 10 min in 4% PFA, permeabilized for 6 min in
0.5% Triton and then blocked for 30 min in blocking solution (5% BSA in PBS). Primary antibodies
were incubated overnight at 4 ◦C in blocking solution (Table 1). After 3 PBS washes, secondary
antibodies were added in blocking solution for 45 min. Mounting medium containing DAPI
(4′,6-diamidino-2-phénylindole; Vectashield, Eurobio Scientific, Les Ulis, France) was added following
3 additional PBS washes. Images were taken on Olympus FV-1200 confocal microscope.
Color profile plot throughout nuclei was obtained using “RGB Profiler” plugin in FiJi
(Image J) software.
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Table 1. List of antibodies and their dilutions used in Western blot (WB) and immunofluorescence
(IF) analyses.
Primary Antibodies Source (Reference Catalog) WB IF
Rabbit anti-Lamin A/C Santa Cruz Biotechnologies (sc-20681) 1:1000 -
Goat anti-Lamin A/C Santa Cruz Biotechnologies (sc-6215) - 1:50
Mouse anti-Lamin A/C Santa Cruz Biotechnologies (sc-376248) - 1:500
Rabbit anti-Lamin B1 Abcam (ab16048) 1:1000 -
Rabbit anti-Lamin B1 Santa Cruz Biotechnologies (sc-6216) - 1:100
Mouse anti-Emerin Novocastra (NCL-emerin) 1:500 1:50
Mouse anti-Nesprin 1α Glenn Morris (MANNES1E) - 1:50
Rabbit anti-Tmem38A Merck Millipore (#06-1005) 1:200 1:50
Rabbit anti-Net39 Proteintech (20635-1-AP) 1:200 -
Rabbit anti-Pcm1 Merck Millipore (HPA023370) - 1:500
Rabbit anti-Samp1a Merck Millipore (#06-1013) 1:200 1:20
Rabbit anti-Desmin Abcam (ab15200) - 1:200
2.5. Western Blotting
Myoblast samples were prepared using 6.5 × 105 proliferating myoblasts. Myotube samples were
prepared from 6.5 × 105 myoblasts plated in 60mm Petri dish in differentiation medium for 4 days. To
avoid contamination of myotube samples with undifferentiated myoblasts, cells trypsinization was
controlled under binocular microscope until detachment of the majority of myoblasts. The medium
was discarded, and the cells were washed in PBS and trypsinized again until detachment of myotubes
and remaining myoblasts. Cell samples were again enriched in myotubes by a short centrifugation
(1 min) at 500 rpm. Myoblast and myotube pellets were extracted using protein extraction buffer
(50 mM Tris-HCl (pH 7.5); 2% SDS; 250 mM sucrose; 75 mM urea; 1 mM dithiothreitol) containing
protease inhibitors (cOmplete ULTRA Tablets, Roche, Meylan, France) and phosphatase inhibitors
(PhosSTOP, Roche). Protein quantification was performed using Pierce BCA Protein Assay kit (Pierce
Biotechnology, ThermoFischer Scientific, illkirch, France). Fifteen to 20 µg of proteins were loaded onto
a 10% acryl/bis-acrylamide gel, separated by SDS-PAGE and transferred onto 0.45 µm Nitrocellulose
membrane. Membranes were stained by Ponceau Red (Sigma-Aldrich), blocked in 5% skim milk or
BSA and then hybridized with primary and secondary antibodies diluted in blocking solution (Table 1).
The revelation was performed using Immobilon® Western (Millipore, Fontenay-sous-Bois, France) or
Clarity-Max (Bio-Rad, Marnes-la-Coquette, France) on a ChemiDoc MP (Bio-Rad).
2.6. Quantitative-RT-PCR
Proliferating and 4-day differentiating cells’ pellets were prepared as detailed above. Total RNA
was extracted using ReliaPrepTM RNA Cell MiniPrep System (Promega, Charbonnières-les-Bains,
France) following manufacturer’s instructions and quantified at the Nanodrop. cDNA was prepared
from 500 µg of total RNA using random hexamer and SuperScript III (Life technologies). Two µg
of cDNA, 0.18 µL of each primers at 20 µM and 4.5 µl of SYBR-Green I Master mix (Roche, Meylan,
France) were used per quantitative-RT-PCR assay and performed in triplicates using Roche LightCycler
480 II (Roche, Meylan, France). The primer list is provided in Table 2.
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Table 2. List of primers used for quantitative RT-PCR.
Gene Name Forward Primer Reverse Primer Ref
Net39 5′-CCCTGGCCCACTAGATAC-3′ 5′-AGAGAAGGCTCCTATGGTCA-3′ [25]
Tmem38A 5′-CAGCTACTTCATCGTCTCCATC-3′ 5′-CTCCCAAAACAGTGCAACATG-3′ [25]
Samp1a 5′-AGATTGAGGTGTACCGCCAC-3′ 5′-TCACTGCTGCTTCTCTGACCT-3′ [26]
Nesprin 1α 5′-GGACTGAGCCTTTCGCTCTG-3′ 5′-GCCACAGTCGCCACGTCTCT-3′ [27]
Rplp0 5′-CTCCAAGCAGATGCAGCAGA-3′ 5′-ATAGCCTTGCGCATCATGGT-3′ [20]
2.7. Statistical Analyses
Statistical analyses of the differences between the number of index cases in EDMD and in
L-CMD mutations reported in the UMD-LMNA database were performed using the Fisher test in
GraphPad Prism.
Statistical analyses of differences in mRNA and protein expression between WT, H222P and dK32
cells were performed using one-way ANOVA in GraphPad Prism.
3. Results
3.1. In Silico Analysis of the UMD-LMNA Database
To gain insight into the differences between EDMD and L-CMD, we first analyzed all mutations
reported for EDMD and L-CMD in the UMD-LMNA locus specific database (http://www.umd.be/
LMNA/). For this analysis, we only considered pure EDMD and L-CMD clinical presentations and
excluded overlapping phenotypes with other laminopathic extramuscular traits. Among the 1678 index
cases reported, 28% are EDMD (464 index cases representing 189 different mutations, corresponding
to 452 heterozygous, 7 homozygous and 5 compounds heterozygous individuals) and only 9% are
L-CMD (150 index cases, representing 66 different mutations, corresponding to 146 heterozygous, 1
homozygous and 3 compound heterozygous individuals) with similar representation of men and
women in both conditions. Compound heterozygous and homozygous individuals were excluded
from further analyses. Apart from nonsense mutations that have not been reported in L-CMD, all
kinds of mutations are observed in EDMD and L-CMD. Most of them are missense mutations in both
conditions, and in frame insertion/deletion is statistically more frequent in L-CMD (p = 0.029; Table 3).
Mutations are found all along the gene, but different hotspots are reported for EDMD (p.Arg453Trp;
18.14% of EDMD index cases) and for L-CMD (p.Arg249Trp; 27.40% of L-CMD index cases) (Figure 1A).
When looking at the distribution of mutations within the different domains, we found that most of the
EDMD index patients (more than 42%) have mutations in the Ig-fold domain compared with 14% of
L-CMD patients (p < 0.0001; Figure 1A and Table 4). The vast majority of L-CMD patients (more than
83%) harbor mutations in coiled–coil domains compared with 50% in EDMD. More specifically, in
L-CMD patients, 36.30% of mutations are in coil 1a and 45.21% in coil 2 compared with 13.27% in coil 1a
(p < 0.0001) and 29.20% in coil 2 (p = 0.0006) for EDMD (Table 4). The α-helical rod domains of Lamin
A/C are essentially coiled–coil motifs made of heptad repeats of amino acids. Amino acid properties
varies depending on their position in the heptad with residues at position a and d involved in the
inter-helical interaction, being mainly hydrophobic residues and residues at position e and g (mainly
charged residues) involved in ionic interactions between the two Lamin molecules within a dimer [28].
Interestingly, among L-CMD patients that harbor missense mutations in coiled–coil domains, most
of them affect residues at e and g position (54.39%) compared with 52.89% for EDMD patients (p =
0.0355; Table 5), followed by 38.60% at position a or d in L-CMD and only 23.14% for EDMD (p = 0.0014;
Table 5). Finally, we analyzed the number of EDMD and L-CMD index cases that have mutations in
residues involved in interactions between two dimers required for tetramer assembly. These residues
are mainly charged residues found in the unstructured head (Met1, Arg7, Arg8, Arg11, Arg25), in coil
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1a (amino acids 31–40, Asp 47, amino acids 65–68), residues located at the end of coil 2 (amino acids
358–364 and 381–385) and in the unstructured tail (amino acids 403–407 and 417–420) as described
in [4]. Here again, we found a significantly higher number of L-CMD patients (40.41%) compared
with EDMD (14.82%; p < 0.0001; Table 6) with mutations affecting these residues. Altogether, these
data imply that L-CMD patients arise from mutations that destabilize Lamin dimers and tetramers
compared with EDMD.
Table 3. Type of mutations among Emery–Dreifuss (EDMD) and LMNA-related congenital muscular
dystrophies (L-CMD) index cases.
Type EDMD (n = 452) L-CMD (n = 146) p-Value
MS 394 (87.17%) 119 (81.51%) 0.1017
NS 3 (0.66%) 0 (0.00%) > 0.99
FS 9 (1.99%) 2 (1.37%) > 0.99
INF 27 (5.97%) 21 (14.38%) 0.0024
SPL 19 (4.20%) 4 (2.74%) 0.6205
Number of index cases with missense (MS), nonsense (NS), frameshift and out-of-frame insertion/deletion (FS), in
frame insertion/deletion (INF) and splice (SPL) mutations among EDMD and L-CMD index cases. P-value in bold
indicate significant differences between EDMD and L-CMD.
Table 4. Localization of mutations within Lamin A domains among EDMD and L-CMD index cases.
Domain (AA Position) EDMD (n = 452) L-CMD (n = 146) p-Value
Head (1–27) 8 (1.77%) 0 (0.00%) 0.2093
Coil 1a (28–66) 60 (13.27%) 53 (36.30%) <0.0001
L1 (67–78) 1 (0.22%) 1 (0.68%) 0.429
Coil 1b (79–222) 35 (7.74%) 3 (2.05%) 0.0111
L12 (223–240) 4 (0.88%) 0 (0.00%) 0.5768
Coil 2 (241–385) 132 (29.20%) 66 (45.21%) 0.0006
Tail N-term part (386–428) 12 (2.65%) 1 (0.68%) 0.2042
Ig-fold (429–549) 191 (42.26%) 21 (14.38%) <0.0001
Tail C-term part (550–664) 9 (1.99%) 1 (0.68%) 0.4642
Number of EDMD and L-CMD index cases with mutations in specific Lamin A domains. Borders of Lamin A/C
domains indicated into brackets were taken from [29,30].
Table 5. Heptad position affected among missense mutations found in coil domains of EDMD and
L-CMD index cases.
Heptad Position EDMD (n = 121) L-CMD (n = 57) p-Value
a/d 28 (23.14%) 22 (38.60%) 0.0014
e/g 64 (52.89%) 31 (54.39%) 0.0355
b/c 20 (16.53%) 4 (7.02%) 0.4736
f 9 (7.44%) 0 (0.00%) 0.1236
Number of index cases with missense mutation in a/d, e/g, b/c and f position among index cases harboring missense
mutations in heptad repeats. Heptad position in Coil 1a, Coil 1b and beginning of Coil 2 as described in [31,32]; and
for the end of Coil 2 as described in [33]. P-value in bold indicate significant differences between EDMD and L-CMD.
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μ
Figure 1. LMNA mutations in EDMD and in L-CMD. (A) Repartition of EDMD and L-CMD index cases
in the UMD-LMNA database along Prelamin A domains. EDMD index cases are reported above the
scheme representing Prelamin A and L-CMD index cases are reported below. The length of the bars
indicates the number of index cases reported with mutations affecting exons at a given position. (B)
Confocal images of human fibroblasts from a control, two EDMD (H222P and R453W) and two L-CMD
(K32del and R249W) patients immunostained with antibody directed against Lamin A/C. Bar graph:
10 µm.
3.2. Phenotype of EDMD and L-CMD Cells in Culture
To further analyze the differences between EDMD and L-CMD mutations, we cultured skin
fibroblasts from two patients with an EDMD phenotype (p.His222Pro and p.Arg453Trp) and two
patients with an L-CMD phenotype (p.Lys32del and p.Arg249Trp), compared to a healthy control.
The fibroblasts from EDMD patients were similar to the control with Lamin A/C localizing mainly at
the nuclear periphery and sparsely in the nucleoplasm (Figure 1B). In comparison, fibroblasts from
L-CMD patients showed a marked increase in nucleoplasmic Lamin A/C (Figure 1B).
To evaluate the consequences of Lamin A/C mislocalization in cells stemming from an affected
tissue, we used primary myoblasts derived from homozygous LmnaH222P mice, a model for EDMD [19],
and from homozygous LmnadK32 mice, a model for L-CMD [20]. These myoblasts recapitulated the
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localization of Lamin A/C observed in patient fibroblasts: i.e., WT- and H222P-Lamin A/C mainly found
at the nuclear periphery and dK32-Lamin A/C apparently exclusively localized in the nucleoplasm
(Figure 2A,B). Interestingly, in dK32-myoblasts, we also observed a partial mislocalization of Emerin in
the cytoplasm. Lamin B1 and Sun2 localization was not affected in any of the myoblasts (Figure 2A
and data not shown). Regarding their expression level, we found a decrease in Emerin levels in H222P










Figure 2. Phenotype of primary myoblasts derived from KI-LmnaH222P and KI-LmnadK32 mouse models.
(A) Confocal images of mouse primary myoblasts from control (WT), KI-LmnaH222P (H222P) and
KI-LmnaK32del (dK32) mice showing immunostainings against Lamin A/C, Emerin and Lamin B1. Bar
graph: 10 µm. (B) Histogram showing pixel intensity for the Lamin A/C staining (red) and DAPI (blue)
along the line traced on WT, H222P and dK32 nuclei of proliferating myoblasts shown on the left.
Bar graph: 10 µm. (C) Western blot analyses of control (WT), H222P and dK32 myoblasts showing
expression level of Lamin A/C, Lamin B1, Emerin. Ponceau Red is used to assess homogeneity in total
protein loaded. (D) Histogram showing the percentage of EdU positive nuclei in WT, H222P and dK32
proliferating myoblasts (top panel) and in four-day differentiating myotubes (lower panel) performed
on at least three different experiments. *: p < 0.05 between H222P and dK32 myotubes. (E) Confocal
images showing four-day differentiating control (WT), H222P and dK32 mouse primary myotubes
stained with anti-Desmin antibody (green) and DAPI (blue). Bar graph: 50 µm. (F) Confocal images of
WT, H222P and dK32 mouse myotubes showing immunostainings against Lamin A/C, Emerin and
Lamin B1. Bar graph: 10 µm. (G) Histogram showing pixel intensity for the Lamin A/C staining (red)
and DAPI (blue) along the line traced on WT, H222P and dK32 nuclei of differentiating myotubes
shown on the left. Bar graph: 10 µm.
We then analyzed the proliferation of mouse primary myoblasts by EdU incorporation in
proliferating myoblast and four days after induction of differentiation. We found a significant increased
proportion of EdU positive dK32-myoblasts in proliferating and differentiating conditions compared
with WT and H222P (Figure 2D), suggesting that L-CMD myoblasts have increased proliferation
capacities leading to delayed cell cycle exits when switched to differentiating conditions. Multinucleated
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myotubes were observed in all lines analyzed at day four following the induction of differentiation with
non-significant differences in fusion indexes between WT and H222P myotubes (WT: 62.5% +/− 7.6
and H222P: 53.0% +/− 1.9; n = 3). Although the fusion index for dK32 myotubes cannot be evaluated
due to highly distorted myonuclei that cannot be properly counted, and four-day differentiating dK32
cultures that are still highly enriched in mono-nucleated cells compared with WT and H222P, as
previously reported [35], revealing myoblast differentiation defects of dK32 myoblasts (Figure 2E).
Interestingly, while WT and H222P myonuclei are round and nicely aligned within myotubes, dK32
myonuclei are severely misshapen, enlarged and elongated, and are aggregated together in the middle
of myotubes (Figure 2F). Compared with staining in myoblasts, Lamin A/C staining in myotubes
shows an increased intensity at the nuclear periphery in WT and H222P myonuclei, but this is still
exclusively nucleoplasmic in dK32 myonuclei (Figure 2G). The localization of other INM proteins,
such as Emerin, Lamin B1 (Figure 2F), Sun2 or Nup153 (not shown) was severely impaired in the dK32
myotubes. Altogether, these data indicate that the nuclear defects are exacerbated with differentiation.
3.3. Impact of Lamin A/C Mislocalization in Myotubes
Myoblast differentiation is in part controlled by the expression of muscle specific NETs involved in
the reorganization of chromatin required to shut off the expression of proliferating genes and to activate
the myogenic program [25,26,36,37]. Following mRNA expression of three of these NETs (Net39/Plpp7;
Tmem38A/Tric-A and Samp1a/Net5/Tmem201) in our myoblasts and myotubes, we observed a significantly
lower expression of Net39 in dK32-myotubes while Tmem38A and Samp1a were efficiently upregulated
(Figure 3A). At the protein level, we observed a significant decrease in the expression of the three
NETs in dK32 myotubes (Figure 3B). In addition, we observed the mislocalization of Tmem38A and
Samp1a in dK32 myotubes (Figure 3C), and this protein mislocalization might be responsible for their
degradation. None of these defects were observed in H222P myotubes. Finally, we analyzed Nesprin-1α
mRNA expression and protein localization. Expression of this isoform increases during myoblast
differentiation [38] and is involved in the reorganization of many centrosomal proteins like Pcm1 at
the ONM, which becomes the origin of microtubule nucleation and organization in myotubes [39,40].
Efficient upregulation of Nesprin-1αmRNA transcription levels were observed during differentiation
of dK32 myoblasts (Figure 3A) however Nesprin-1α proteins were mislocalized in dK32-myotubes
(Figure 3C) as other centrosomal proteins such as Pcm1 (data not shown). None of these defects were
observed in H222P myotubes. To investigate the potential defects of microtubules due to improper
Nesprin-1α and centrosomal protein expression and localization, we followed microtubule regrowth
after nocodazole treatment in WT and dK32-myocytes (i.e., post-mitotic myoblasts before their fusion).
Nocodazole induces a complete microtubule depolymerization. After the washout of the drug, WT
myocytes regrow microtubule from their ONM that have integrated pericentriolar materials like Pcm1
(Figure 3D). Unlike WT myocytes, dK32-myocytes have only few microtubule regrowth from the
ONM but present additional spots of microtubule nucleation from Pcm1-positive area in the cytoplasm
(Figure 3D).
To discriminate between the roles played by 1) decreased Lamin A/C expression/absence from
the nuclear lamina and 2) accumulation of nucleoplasmic Lamin A/C in the pathomechanism of
dK32-Lmna cells, we used primary myoblasts derived from Lmna-KO mouse models [2] and WT
primary myoblasts stably expressing DARPin molecules that interact with Lamin A/C and either
displace it to the nucleoplasm (LaA_1 and LaA_2) or do not (LaA_3 and LaA_4), as well as control
DARPin E3.5 that neither binds nor displaces Lamin A/C [23]. Proliferating Lmna-KO myoblasts have
particularly elongated nuclei with partial Emerin mislocalization to the cytoplasm and an absence of
Lamin B1 at some nuclear poles (Figure 4A). WT myoblasts expressing DARPin LaA_1 (not shown) or
LaA_2 that have a partial mislocalization of Lamin A/C to the nucleoplasm, showed nuclear elongation
and a partial mislocalization of Emerin as well (Figure 4B). No defects were observed with the 3
control DARPins: LaA_3, LaA_4 (not shown) and E3.5 with regard to NE protein localization and
nuclear shape (Figure 4B). When switched to differentiation medium, Lmna-KO myotubes formed
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normally with moderately misshapen myonuclei compared with dK32 (Figure 4C). In comparison,
DARPin-induced nucleoplasmic accumulation of Lamin A/C lead to widely enlarged nuclei quite
similar to those observed in dK32 myotubes, with moderate Emerin and Lamin B1 mislocalization
(Figure 4D). Myonuclei expressing control DARPin LaA_3, LaA_4 and E3.5 were not affected. Regarding
the upregulation of muscle specific NETs during myogenesis, Lmna-KO myotubes showed a strong
impact on the upregulation of Net39, Samp1a and Nesprin-1α (Figure 4E), while their transcriptional
activation was efficient in DARPin-expressing myotubes (Figure 4F). Altogether, it seems that both










Figure 3. Defective expression and localization of muscle specific nuclear envelope transmembrane
proteins (NETs). (A) Dot plots showing Net39, Tmem38A, Samp1a and Nesprin-1αmRNA expression
level in myoblasts (Mb) and four-day differentiating WT (black; at least n = 5), H222P (blue; at least n =
5) and dK32 (orange; n = 6) myotubes (MT) normalized to Rplp0 expression. *: p < 0.05; ***: p < 0.001. (B)
Western blots showing Net39, Tmem38A and Samp1a protein level in four-day differentiated WT and
H222P myotubes (left) and WT and dK32 myotubes (right). (C) Confocal images showing Tmem38A,
Samp1a and Nesprin-1α (Nesp1α) immunostainings in WT, H222P and dK32 four-day differentiated
myotubes. Bar graph: 10 µm. (D) Confocal images showing α-Tubulin and Pcm1 immunostaining in
WT and dK32 myoblasts five min after Nocodazole washout. The monochrome pictures are presented
in color (green: α-Tubulin; red: Pcm1) overlaid with DAPI (blue) on the right. A magnification of the
area surrounded with white dotted line on dK32 is shown on the bottom panel. Bar graph: 10 µm.






Figure 4. Analysis of the phenotype of Lmna-KO and DARPin expressing myoblasts. (A,B) Confocal
images showing mouse primary myoblasts (A) and myotubes (B) derived from WT and Lmna-KO
mice immunostained for Lamin A/C, Emerin or Lamin B1. Bar graph: 10 µm. (C,D) Confocal images
showing mouse primary myoblasts (C) and myotubes (D) derived from WT mouse stably expressing
LaA_2-, LaA_3- and E3.5-DARPin immunostained for Lamin A/C, Emerin or Lamin B1. Bar graph:
10 µm. (E,F) Dot plots showing Net39, Tmem38A, Samp1a and Nesprin-1αmRNA level in myoblasts
(Mb) and four-day differentiated WT (black; at least n = 3) and Lmna-KO (red; at least n = 4) myotubes
(MT) normalized to Rplp0 expression. *: p < 0.05; ***: p < 0.001 (E) or in myoblasts (Mb) and four-day
differentiated E3.5- (black; n = 6); LaA_2- (pink; at least n = 8), LaA_3-DARPin (purple; at least n = 11)
and myotubes (MT) normalized to Rplp0 expression. *: p < 0.05 (F).
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4. Discussion
Laminopathies correspond to a highly heterogeneous group of disorders affecting either tissues
in an isolated fashion (such as striated muscle laminopathies, metabolic syndromes or peripheral
neuropathies) or with a systemic involvement mainly observed in premature ageing syndromes and
overlapping laminopathies [15,16]. Many hypotheses have been proposed to explain why mutations
in a ubiquitous protein give rise to disorders that selectively affect tissues [15,41], but so far no studies
have addressed the variability in disease severity in a given group of laminopathies. This is particularly
true for striated muscle laminopathies, ranging from the early and devastating L-CMD [17] to moderate
EDMD and LGMD1B forms, with mutations found all along the gene, while for other laminopathies
only a few mutations have been reported with major mutational hot spots.
4.1. L-CMD Mutations Strongly Affect Lamin A/C Properties
Pooling the results from our in silico and in vitro data, we speculate that L-CMD mutations are
responsible for a pronounced assembly defect of mutant Lamin A/C while EDMD mutations probably
only lead to weaker interactions within Lamin A/C filaments and/or perturbed interactions with its
partners. Indeed, we show that L-CMD patient fibroblasts and dK32-Lmna mouse myoblasts always
presented increased nucleoplasmic Lamin A/C (Figure 1B, Figure 2A,B). A similar nucleoplasmic
accumulation of Lamin A/C was previously reported with various L-CMD mutations [31,33] leading to
the idea that this might be a common feature of all L-CMD mutations. If this nucleoplasmic localization
is only partial for patient fibroblasts reflecting their heterozygous status (Figure 1B), it is exclusively
nucleoplasmic in mouse cells that are homozygous for the mutation (Figure 2A,B).
Although its structure has not yet been characterized, nucleoplasmic lamin is thought to correspond
to a poorly polymerized form of Lamin A/C [23,29,30,32]. It is well established that the coiled–coil
structure of the rod domain is directly involved in dimer formation [42–44]. Interestingly, we find that
most of L-CMD patients harbor mutations in these domains compared with EDMD patients (Table 4),
and more specifically 1) in charged residues at e and g positions within the heptad (Table 5), which
are involved in ionic interactions between two adjacent Lamin molecules to form a Lamin dimer or
2) in the charged residues localized at the rod domain extremities (Table 6) involved either dimer
stabilization or tetramer formation in a mutually exclusive way [4]. In line with our observations,
several disease-associated mutations in Lamin coil 2 were more deeply investigated on their ability
to stabilize or destabilize Lamin dimers, showing that mutations leading to early onset myopathies
stabilize Lamin dimers, thus hampering further polymerization into filaments [45]. Moreover, Lamin
assembly defects have also been reported by in vitro assembly experiments using human or C. elegans
A-type Lamin L-CMD mutants [46,47].
4.2. The Importance of Polymerized Lamin A/C for Chromatin Organization during Myoblast Differentiation
We took advantage of our access to patient fibroblasts and two of the published KI-mouse models
for striated muscle laminopathies to look for specific pathomechanisms for EDMD or L-CMD. We
found an accumulation of nucleoplasmic Lamin A/C only in cells with L-CMD mutations (Figure 1B,
Figure 2A,B,F,G). If the consequences of this increased nucleoplasmic Lamin A/C pool are somehow
limited in proliferating myoblasts, major defects are observed during their differentiation, when the
nucleoplasmic pool of Lamin A/C almost disappears from WT cells (Figures 2 and 3). This suggests
that efficient myoblast differentiation requires either Lamin A/C at the nuclear lamina, probably
to reorganize chromatin and the microtubule network, and/or reduced nucleoplasmic Lamin A/C,
therefore inhibiting its function in cell cycle regulation [48]. Indeed, many of the functions of Lamin
A/C at the nuclear periphery relate to the sequestration of integral proteins to the nuclear envelope.
Among them, SUN and Nesprin proteins were shown to be essential to reorganize the microtubule
network during myoblast differentiation [40,49]. In addition, data obtained from Lmna-KO myoblasts
and from myoblasts where Lamin A/C was artificially displaced to the nucleoplasm indicate that both
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absence of peripheral Lamin and its nuclear accumulation are responsible for the defects observed in
dK32 myotubes (Figure 4).
Organization of the genome within cells is not random. Repressed chromatin/heterochromatin
is mainly found in close proximity to the INM and active chromatin/euchromatin within the nuclear
interior. A role of Lamin A/C was described in transcriptional repression by sequestration of
heterochromatin domains close to the INM [50,51], while it interacts with euchromatin in the nuclear
interior [52]. It is now well established that the active or repressive functions of Lamin A/C are indirect
and require its interaction with other proteins [2,52]. At the nuclear periphery, Lamin A/C interacts
with ubiquitous NETs like Emerin and Lap2β that recruit the histone deacetylase Hdac3 [53,54] and
tissue-specific NETs were recently involved in genome organization in a tissue-specific manner [25,55,56].
Interestingly, we found Emerin to be mislocalized in mouse L-CMD cells and the three muscle-specific
NETs that we analyzed (Net39, Tmem38A and Samp1a) are expressed at lower levels and mislocalized
in L-CMD mouse myotubes (Figures 2 and 3). Although we did not found defect in Net39, Tmem38A
or Samp1a localization in myotubes from our EDMD mouse model, Samp1 loss at the nuclear poles
was reported in EDMD patient’s myotubes [57]. Finally, despite the fact that we did not analyze all
muscle-specific NETs nor the epigenetic state of dK32 myonuclei, we can hypothesize that chromatin
organization is altered in L-CMD, as previously shown for the L-CMD p.Arg388Pro mutant in HeLa
cells [58].
Altogether, we think that Lamin A/C in the nuclear lamina has a fundamental role in chromatin
reorganization during myoblast differentiation by the sequestration of ubiquitous and muscle-specific
NETs at the INM. L-CMD mutations are responsible for major defects in Lamin A/C polymerization,
impacting on NETs tethering to the INM and subsequent chromatin reorganization required for efficient
cell cycle exit and activation of myogenesis. We can hence propose that L-CMD mutations impact
proper post-natal muscle development. In comparison, EDMD mutations, by weakening of the nuclear
lamina, may be more prone to DNA damage and therefore involved in defects of muscle maintenance.
Since both decreased Lamin A/C level within the nuclear lamina and increased nucleoplasmic Lamin
A/C levels are responsible for L-CMD pathogenesis, an efficient therapeutic approach for this disorder
will have to deal with both increasing Lamin A/C levels at the nuclear lamina and decreasing levels in
the nucleoplasm.
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